META Pharmaceuticals Inc. (META) focuses on immune metabolism to develop next-generation autoimmune therapies with enhanced efficacy and safety. Metabolic pathways critically regulate immune cell function, and their dysregulation drives inflammation and tissue damage in conditions like Inflammatory Bowel Disease (IBD). By rebalancing metabolism, inflammation and tissue damage can be reversed and resolved.

As a pioneer in immune metabolism, META is building a broad pipeline of first-in-class therapies to reverse disease progression while minimizing systemic toxicity. The leading pipeline is the world's 1st oral inhibitor for autoimmune diseases. Preclinical studies demonstrate its superior efficacy to anti-TNFα, anti-IL12/23, anti-TL1A, and Upadacitinib in IBD models, with a >600-fold therapeutic window. This inhibitor also shows promise for Atopic Dermatitis, Multiple Sclerosis, and Primary Biliary Cholangitis. META also develops another novel treatment for Primary Hyperoxaluria.